Prescribing Clinical Network

Policy Statement	Pegloticase for treating severe debilitating chronic tophaceous gout
Policy No:	PCN 366-2018 (replaces PCN 66-2013)
Date of Issue	September 2018
Review Date:	*September 2021* *(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)*

Recommendations:

The Prescribing Clinical Network does not recommend the use of pegloticase for treating severe debilitating chronic tophaceous gout, as its marketing authorisation has been withdrawn in the UK/EU.

Pegloticase is considered to have a BLACK status on the traffic light system.

Key Considerations:

- On 30 June 2016 the European Commission withdrew the marketing authorisation for Krystexxa (pegloticase) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Crealta Pharmaceuticals Ireland Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.
- Krystexxa was granted marketing authorisation in the EU on 8 January 2013 for treatment of chronic gout. The marketing authorisation was initially valid for a 5-year period.
- The European Public Assessment Report (EPAR) for Krystexxa will be updated accordingly to indicate that the marketing authorisation is no longer valid.
- This is a review of the PCN recommendation made in July 2013.

Date taken to Prescribing Clinical Network	5th September 2018
Agreed by PCN members	18th September 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG